Palvella Therapeutics (PVLA) Other Operating Expenses (2013 - 2023)
Palvella Therapeutics (PVLA) reported Other Operating Expenses of -$14.9 million for Q4 2023, down 200.0% on a QoQ basis from $14.9 million in Q3 2023.
Palvella Therapeutics (PVLA) has 2 years of Other Operating Expenses data on file, last reported at -$14.9 million in Q4 2023.
- Quarterly Other Operating Expenses changed N/A year-over-year to -$14.9 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was -$14.9 million (down 200.0% YoY) and the FY2023 annual result came in at $23.1 million, changed N/A from the prior year.
- Other Operating Expenses slipped to -$14.9 million in Q4 2023 per PVLA's latest filing, from $14.9 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $14.9 million in Q3 2023 and bottomed at -$14.9 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -14.89 Mn |
| Sep 30, 2023 | 14.89 Mn |
| Dec 31, 2013 | 2,198.00 |
| Sep 30, 2013 | 5,750.00 |